MPLA (synthetic) Sterile Solution
320 CHF CHF 320.00
AG-CU1-0002-C100100 µgCHF 320.00
|Synonyms||Monophosphoryl Lipid A; Phosphorylated Hexaacyl Disaccharide; Glycopyranoside Lipid A; Glucopyranosyl Lipid Adjuvant; GLA|
|Source/Host Chemicals||Synthetic. Does not contain RNA, DNA or protein fragments.|
|Purity Chemicals||No detectable TLR4 independent activity: standardised TLR4-specific agonist.|
|Appearance||Colourless opaque aqueous solution.|
|Concentration||0.5mg/ml stabilized in sterile, double-distilled water (ddWater), without any additives.|
|Other Product Data||
Preparation of Stock Solution: To yield a 50μg/ml (500-50x) stock solution add 100μl of MPLA to 900μl endotoxin-free and sterile ddWater (Cat. No.: IAX-900-002) (not PBS) and mix well.
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||+4°C|
Do not freeze.
Ready-made solution is cell culture-grade. Prepare diluted MPLA working solutions in water just prior to use, keep sterile.
|Use/Stability||Stable for at least 2 years after receipt when stored at +4°C.|
|Product Specification Sheet|
- Toll-like receptor 4 (TLR4) activator. Activates TLR4 but does not activate TLR2 even at high concentrations.
- Defined structure of MPLA.
- Synthetic lipid A is structurally very similar to natural MPLA but does not exist in nature.
- Biological activities of synthetic lipid A analogs: pyrogenicity, lethal toxicity, anticomplement activity, and induction of gelation of Limulus amoebocytelysate: K. Tanamoto, et al.; Infect. Immun. 44, 42 (1984)
- Endotoxic properties of chemically synthesized lipid A part structures. Comparison of synthetic lipid A precursor and synthetic analogues with biosynthetic lipid A precursor and free lipid A: C. Galanos, et al.; Eur. J. Biochem. 140, 221 (1984)
- Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A: M. Martin, et al.; Infect. Immun. 71, 2498 (2003)
- Cell activation by Porphyromonas gingivalis lipid A molecule through Toll-like receptor 4 and myeloid differentiation factor 88-dependent signaling pathway: M. Martin, et al.; Int. Immunol. 14, 1325 (2003)
- Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants: C.B. Fox, et al.; Subcell. Biochem. 53, 303 (2010)
- A synthetic adjuvant to enhance and expand immune responses to influenza vaccines: R.N. Coler, et al.; PLoS One 5, e13677 (2010)
- CD14 and TRIF govern distinct responsiveness and responses in mouse microglial TLR4 challenges by structural variants of LPS: T. Regen, et al.; Brain Behav. Immun. 25, 957 (2011)